Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Capecitabine (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Status changed from not yet recruiting to recruiting.